Category

Archives

Androgen Receptor

Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance

4 views | Mar 20 2020

Li C et al. provided critical insight into the mechanism of enzalutamide resistance in PCa, potentially offering a therapeutic avenue for enhancing the efficacy of enzalutamide to better manage this common malignancy. [Read the Full Post]

Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer

3 views | Mar 20 2020

Chu YY et al. suggested that combined inhibition of c-MET and EGFR could potentially re-sensitize TNBC to the cytotoxic effects of PARPi. [Read the Full Post]

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors

50 views | Nov 03 2019

Poddubskaya E et al. showed that transcriptomic-guided sequential personalized prescription of targeted therapies can be effective in terms of survival and quality of life in ALK-mutated NSCLC. [Read the Full Post]

Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience

50 views | Oct 07 2019

Chang LW et al. found that AA and ENZ had a similar efficacy in treating post-docetaxel mCRPC patients. Metastatic volume and nadir PSA were independent risk factors of these patients in predicting their disease-specific survival and overall survival. [Read the Full Post]

Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide

51 views | Oct 06 2019

Metz EP et al. indicated that NE marker expression can increase independently of the sensitivity to enzalutamide. [Read the Full Post]

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo

134 views | Jul 15 2019

Kuruma H et al. provided a preclinical proof-of-principle that Compound 30 could be a promising next generation anti-AR agent, especially in the context of antiandrogen-resistant tumors. [Read the Full Post]

Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration Resistant Prostate Cancer

151 views | Mar 30 2019

Kregel S et al. identified increases in polyunsaturated fatty acids (PUFAs) and Thioredoxin-interacting protein (TXNIP) as potential pharmacodynamics biomarkers for targeting BET proteins. [Read the Full Post]

Role of connexin 43 in cadmium-induced proliferation of human prostate epithelial cells

193 views | Jan 26 2019

Liu Q et al. found that Cx43 might be a target for prostatic diseases associated with Cd exposure. [Read the Full Post]

Robust and stimuli-responsive POSS hybrid PDMAEMA hydrogels for controlled drug release

330 views | Aug 30 2018

Chen Y, et al. showed that the increased Oa-POSS could improve the drug loading ability, and OP-PD gels showed well controlled-release effect in simulated human stomachic condition. [Read the Full Post]

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer

0 views | Feb 26 2018

Luo J et al. suggested that the combination of bicalutamide and PARP inhibitor may be a potential strategy for TNBC patients and merits further evaluation. [Read the Full Post]